STADA Arz achieves 15% profit growth to 713 million euros

11 March 2021

STADA Arzneimittel, the Germany-based drugmaker owned by UK private equity funds Cinven and Bain Capital, has reported revenues of 3 billion euros ($3.6 billion) for full-year 2020, alongside double-digit growth well ahead of the market.

Organic sales growth of 6% and total growth of 18% in a flat market were complemented by seven acquisitions and more than 80 in-licensing transactions closed during 2020, the company noted.

Earnings before interest, tax, depreciation and amortization (EBITDA) increasing by 15% at constant currencies to 713 million euros. Investments in the supply chain strengthened STADA’s sustainability, with record output, strong supply levels and zero critical observations from regulatory inspections of manufacturing facilities in 2020.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK